勘误：基于16S rRNA、宏基因组测序和网络药理学揭示化滞柔肝颗粒通过肠道菌群治疗非酒精性脂肪肝的机制
Corrigendum: Revealing the mechanism of Huazhi Rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology.
作者信息
Liu Yingying, Tan Yingying, Huang Jiaqi, Wu Chao, Fan Xiaotian, Stalin Antony, Lu Shan, Wang Haojia, Zhang Jingyuan, Zhang Fanqin, Wu Zhishan, Li Bing, Huang Zhihong, Chen Meilin, Cheng Guoliang, Mou Yanfang, Wu Jiarui
机构信息
Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu, China.
出版信息
Front Pharmacol. 2023 Jul 26;14:1243304. doi: 10.3389/fphar.2023.1243304. eCollection 2023.
Abstract
[This corrects the article DOI: 10.3389/fphar.2022.875700.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fphar.2022.875700。]
相似文献
1
Corrigendum: Revealing the mechanism of Huazhi Rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology.勘误：基于16S rRNA、宏基因组测序和网络药理学揭示化滞柔肝颗粒通过肠道菌群治疗非酒精性脂肪肝的机制
Front Pharmacol. 2023 Jul 26;14:1243304. doi: 10.3389/fphar.2023.1243304. eCollection 2023.
2
Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology.基于16S rRNA、宏基因组测序和网络药理学揭示化滞柔肝颗粒通过肠道菌群治疗非酒精性脂肪肝的机制
Front Pharmacol. 2022 Apr 26;13:875700. doi: 10.3389/fphar.2022.875700. eCollection 2022.
3
Efficacy and safety of Huazhi Rougan granule in the treatment of non-alcoholic fatty liver: a systematic review and meta-analysis.化滞柔肝颗粒治疗非酒精性脂肪肝的疗效与安全性：一项系统评价和Meta分析
Ann Palliat Med. 2021 Dec;10(12):12969-12984. doi: 10.21037/apm-20-1613. Epub 2021 Feb 23.
4
Effects of Zhishi Daozhi Decoction on the intestinal flora of nonalcoholic fatty liver disease mice induced by a high-fat diet.止食导滞汤对高脂饮食诱导的非酒精性脂肪肝病小鼠肠道菌群的影响。
Front Cell Infect Microbiol. 2023 Jan 4;12:1005318. doi: 10.3389/fcimb.2022.1005318. eCollection 2022.
5
[Huazhi Rougan Granules attenuates steatosis in cell model of nonalcoholic fatty liver disease by inducing autophagy].华致柔肝颗粒通过诱导自噬减轻非酒精性脂肪性肝病细胞模型中的脂肪变性
Zhongguo Zhong Yao Za Zhi. 2023 Apr;48(7):1770-1778. doi: 10.19540/j.cnki.cjcmm.20221111.401.
6
[Zuogui Jiangtang Qinggan Prescription promotes recovery of intestinal mucosal barrier in mice with type 2 diabetes mellitus and nonalcoholic fatty liver disease by improving intestinal flora homeostasis].左归降糖清肝方通过改善肠道菌群稳态促进2型糖尿病合并非酒精性脂肪性肝病小鼠肠黏膜屏障的恢复
Zhongguo Zhong Yao Za Zhi. 2023 Jan;48(2):525-533. doi: 10.19540/j.cnki.cjcmm.20220913.703.
7
Integrated serum pharmacochemistry, 16S rRNA sequencing and metabolomics to reveal the material basis and mechanism of Yinzhihuang granule against non-alcoholic fatty liver disease.整合血清药物化学、16S rRNA测序和代谢组学以揭示茵栀黄颗粒抗非酒精性脂肪性肝病的物质基础和作用机制。
J Ethnopharmacol. 2023 Jun 28;310:116418. doi: 10.1016/j.jep.2023.116418. Epub 2023 Mar 27.
8
Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice.中药方剂化脂柔肝通过增强小鼠粪便胆汁酸排泄减轻非酒精性脂肪性肝炎
Front Pharmacol. 2022 Jun 1;13:833414. doi: 10.3389/fphar.2022.833414. eCollection 2022.
9
[Intestinal flora polymorphisms with different lesional stages in an animal model of MAFLD].[非酒精性脂肪性肝病动物模型中不同病变阶段的肠道菌群多态性]
Zhonghua Gan Zang Bing Za Zhi. 2021 Nov 20;29(11):1069-1076. doi: 10.3760/cma.j.cn501113-20200826-00478.
10
Network pharmacology-based investigation to explore the effect and mechanism of Erchen decoction against the nonalcoholic fatty liver disease.基于网络药理学的研究，探索二陈汤治疗非酒精性脂肪性肝病的作用及机制。
Anat Rec (Hoboken). 2021 Nov;304(11):2605-2619. doi: 10.1002/ar.24770. Epub 2021 Sep 18.
Zotero 插件